METHODS FOR TREATING NEUROGENIC INFLAMMATION

• US 20090028908A1
• Filed: 08/06/2008
• Published: 01/29/2009
• Est. Priority Date: 02/25/2002
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Donovan, Stephen
• Application Number:
  US12/187,230
• Publication Number:
  US 20090028908A1
• Time in Patent Office: Days
• US Class Current: 424/239.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/046 Tachykinins, e.g. eledoisins, substance P; Related peptides
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.

Claims

1. A method for treating neurogenic inflammation in a patient, the method comprising the step of administering a therapeutically effective amount of an agent to the patient, the administration reducing the secretion of inflammation producing molecules thereby treating the neurogenic inflammation,

wherein the agent comprises a fusion protein including a botulinum toxin proteolytic domain, a botulinum toxin heavy chain H_N and a targeting moiety, and

wherein the targeting moiety is a substance P or a substance P component effective in binding to a substance P receptor.

2. The method according to claim 1, wherein the botulinum toxin proteolytic domain is a botulinum toxin serotype A proteolytic domain, a botulinum toxin serotype B proteolytic domain, a botulinum toxin serotype C1 proteolytic domain, a botulinum toxin serotype D proteolytic domain, a botulinum toxin serotype E proteolytic domain, a botulinum toxin serotype F proteolytic domain, or a botulinum toxin serotype G proteolytic domain.

3. The method according to claim 1, wherein the botulinum toxin heavy chain H_N is a botulinum toxin serotype A heavy chain H_N, a botulinum toxin serotype B heavy chain H_N, a botulinum toxin serotype C, heavy chain H_N, a botulinum toxin serotype D heavy chain H_N, a botulinum toxin serotype E heavy chain H_N, a botulinum toxin serotype F heavy chain H_N, or a botulinum toxin serotype G heavy chain H_N.

4. The method according to claim 1, wherein the botulinum toxin proteolytic domain comprises a botulinum toxin serotype A proteolytic domain.

5. The method according to claim 1, wherein the botulinum toxin heavy chain H_N comprises a botulinum toxin serotype A heavy chain H_N.

6. The method according to claim 1, wherein the agent is administered systemically.

7. The method according to claim 6, wherein the systemic administration is oral administration, intravenous administration, or administration as an inhalant.

8. The method according to claim 1, wherein the agent is administered subcutaneously or intramuscularly.

9. A method for treating neurogenic inflammation in a patient, the method comprising the step of administering a therapeutically effective amount of an agent to the patient, the administration reducing the secretion of inflammation producing molecules thereby treating the neurogenic inflammation,

wherein the agent comprises a fusion protein including a botulinum neurotoxin LH_N fragment and a targeting moiety, and

wherein the targeting moiety is a substance P or a substance P component effective in binding to a substance P receptor.

10. The method according to claim 9, wherein the botulinum neurotoxin LH_N component is a botulinum neurotoxin serotype A LH_N fragment, a botulinum neurotoxin serotype B LH_N fragment, a botulinum neurotoxin serotype C, LH_N fragment, a botulinum neurotoxin serotype D LH_N fragment, a botulinum neurotoxin serotype E LH_N fragment, a botulinum neurotoxin serotype F LH_N fragment, or a botulinum neurotoxin serotype G LH_N fragment.

11. The method according to claim 9, wherein the botulinum toxin heavy chain LH_N fragment comprises a botulinum toxin serotype A heavy chain LH_N fragment.

12. The method according to claim 9, wherein the agent includes one or more spacer regions between the LH_N fragment and the targeting moiety.

13. The method according to claim 9, wherein the agent is administered systemically.

14. The method according to claim 13, wherein the systemic administration is oral administration, intravenous administration, or administration as an inhalant.

15. The method according to claim 9, wherein the agent is administered subcutaneously or intramuscularly.